Study: Testosterone Therapy Does Not Raise Risk for Aggressive Prostate Cancer
World Meeting, ESSM Research Grants: June 30 Deadlines to Watch
American and Swedish researchers have reported that testosterone replacement therapy (TRT) does not increase a man's risk for aggressive prostate cancer.
Their study involved almost a quarter million Swedish men.
The researchers analyzed medical records from two Swedish databases. Between 2009 and 2012, 284 men with prostate cancer and 1,378 men without prostate cancer filled prescriptions for TRT.
Risk for aggressive disease was cut in half for men who were on TRT for a year or more. The study authors wrote that this result was "a novel finding that warrants further investigation."
The team did find a connection between TRT and "favorable risk" prostate cancer. However, this result might have occurred because of early biopsies and frequent doctor visits.
“Overall, our study suggests that what is best for men’s health is to keep testosterone levels balanced and within a normal range,” said lead investigator and urologist Stacy Loeb, MD, MSc of the NYU Langone Medical Center in a press release.
The findings were presented in May at the American Urological Association's annual meeting in San Diego, California. To learn more, please click here.
June is going by fast and we would like to remind you of two important deadlines on June 30, 2016.
World Meeting on Sexual Medicine: Don't miss this opportunity to connect with your colleagues September 22-25, 2016 in Beijing, China! To take advantage of early bird fees, your registration payment must be received before June 30, 2016. Full details are available here.
ESSM Research Grants: The European Society for Sexual Medicine (ESSM) has issued a call for its annual research grants. Each year, the ESSM grants up to EUR 30,000 to fund three to four research projects with a maximum duration of 18 months. Application forms are due by
June 30, 2016. All applicants are encouraged to read these frequently asked questions.